Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   GTC BIOTHERAPEUTICS RECEIVES NOTICE OF ALLOWA

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,880   +0,009   (+1,09%) Dagrange 0,874 - 0,882 430.357   Gem. (3M) 6,2M

GTC BIOTHERAPEUTICS RECEIVES NOTICE OF ALLOWA

Volgen
13 Posts
| Omlaag ↓
  1. frederic_knight 9 januari 2006 15:03
    GTC BIOTHERAPEUTICS RECEIVES NOTICE OF ALLOWANCE ON TRANSGENIC PRODUCTION PATENT



    FRAMINGHAM, MA – January 9, 2006 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for the claims in its patent application 07/938,322 covering the production of therapeutic proteins in the milk of transgenic mammals. The allowed claims, which are expected to issue in the next several weeks, include all classes of proteins in all mammals and will provide GTC with a strong intellectual property position regarding the development and use of this technology for US markets. The patent that is expected to issue from this application will not expire until 2021.



    “GTC has an extensive intellectual property portfolio for the production of therapeutic proteins in milk and we will continue to use our broad IP position to encourage the adoption of transgenic production technology by our collaborators and partners,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman and Chief Executive Officer. “This broad patent will provide long term protection for GTC's proprietary products in the USA, including our lead program for ATryn®.”



    GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. ATryn® is also in a pivotal phase III study for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency who are undergoing high-risk procedures, such as surgery or childbirth. GTC anticipates using the results from this clinical study to prepare a Biologics License Application for the United States Food and Drug Administration.



    Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties.



    GTC is able to produce a therapeutic protein in an animal’s milk through a process known as transgenic technology. GTC couples the gene expressing a specific protein with a specific milk protein promoter gene and incorporates it into an animal’s genome such that the protein is expressed during lactation. This approach enables the production of therapeutic proteins that are difficult to express through traditional production methods. For those products that can be expressed with conventional recombinant technologies, transgenic technology has significantly lower capital requirements to establish large volume capacity.



    About GTC Biotherapeutics, Inc.

    GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.



    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the likely issuance of GTC’s newest patent and its patent position going forward. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with intellectual property and patents. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
  6. [verwijderd] 9 januari 2006 21:57
    t zou toch aardig zijn over dit bericht wat meer licht te laten schijnen.
    Tis tenslotte niet niks dat de technology nu in de positieve schijnwerper staat.
    Enkelen denken dat GTCB hier alleen de vruchten van zullen plukken,anderen zien het bericht als de aftrap voor pharmings succes.
  12. [verwijderd] 10 januari 2006 00:19
    leuke stijging bij gtcb
    lijkt me een prima teken

    de hele wereld gaat straks aan de biotech, met al die miljsarden menden zullen we wel moeten

    ik weet het: een dronkaard kan wel een wacko zijn, maar hij spreekt de waarheid en soms is hij een profeet.

    je moet gewoon pharming in ke porto hebben
  13. [verwijderd] 11 januari 2006 09:44
    quote:

    dollie schreef:

    [quote=camobs]
    Nou Doll, reik mij eens een vrucht aan.

    groet
    [/quote]
    yahoo.businessweek.com/magazine/conte...

    doll

    leuk he van 16 januari!
    oh jee,cambeur,alweer plagiaat!!Deze was je zeker niet opgevallen he?
    Nou kijk het geeft maar aan dat iedereen wel eens wat tegenkomt en het dan plaatst zonder te verifieren of iemand anders het op een of ander ander forum al geplaatst heeft.Een zuurpruim die hier op let.
13 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Pharming stemt over nieuwe CEO
  2. Pharming presenteert nieuwe CEO
  3. Fundlogic verkoopt bijna geheel belang in Pharming
  4. Fundlogic flink groter in Pharming
  5. DWS meldt groter belang in Pharming
  6. Morgan Stanley groter in Pharming
  7. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  8. RBC verhoogt koersdoel Pharming fors
  9. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  10. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster